Immunic (IMUX) News
NASDAQ: IMUXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
6.99-0.40 (-5.41%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IMUX news summary
We found 7 recent headlines mentioning Immunic (IMUX): 0 in the past week and 4 in the past 30 days, most often from Nasdaq, PR Newswire. IMUX is making an outsized move today, down 5.41% at $6.99, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Immunic Q3 Loss Widens On Higher Expenses; Phase 3 MS Trial Data Expected In December 2026", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Immunic headlines
- Immunic Q3 Loss Widens On Higher Expenses; Phase 3 MS Trial Data Expected In December 2026(RTTNews) - Immunic, Inc. (IMUX) reported third-quarter 2026 financial results, reflecting a wider net loss driven by increased research and development and general and administrative expenses. The…NasdaqIMUX, BRK.A
- Immunic, Inc. Hosts Progressive Multiple Sclerosis Research and Development Day Webinar on November 5, 2026Immunic, Inc. is hosting a Progressive Multiple Sclerosis (PMS) Research and Development Day webinar on Thursday, November 5, 2026, from 12:30 p.m. to 2:00 p.m. ET via video conference. The company…Nasdaq
- Immunic to Participate in Investor Conferences in NovemberNEW YORK, Nov. 2, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced…PR Newswire
- Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced…PR Newswire
- New Strong Buy Stocks for October 22ndBBCP, UCB, TGS, STX and IMUX have been added to the Zacks Rank #1 (Strong Buy) List on October 22, 2026.NasdaqSTX, TGS, BBCP, IMUX
- Immunic Names Jaa Roberson Chief People Officer(RTTNews) - On Monday, Immunic, Inc. (IMUX), a biotechnology company developing oral treatments for neurological diseases, appointed Jaa Roberson as Chief People Officer, effective immediately. She…Nasdaq
- Immunic Appoints Jaa Roberson as Chief People Officer– Appointment Supports Immunic's Strategy to Build a Leading Multiple Sclerosis Organization Ahead of Potential Transition to Fully Integrated Commercial Company – NEW YORK, Oct. 19, 2026…PR Newswire